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Abstract 18 
Background/Aims:  19 
The aim of this systematic review was to evaluate clinical trial data regarding the effect of 20 
resveratrol supplementation on cognitive performance and mood in populations that are 21 
healthy and in the clinical setting. 22 
Methods: Using the PRISMA guidelines, a systematic literature review of randomized 23 
controlled trials was conducted. A meta-analysis was also conducted to determine treatment 24 
effect on the following cognitive domains and mental processes: processing speed, number 25 
facility, memory, and mood. Risk of bias was assessed using the Cochrane Collaboration 26 
Risk of Bias tool; and quality of the body of evidence assessed by GRADE. 27 
Results/Discussion: Ten studies were included. Three studies reported resveratrol 28 
supplementation to significantly improve some measures of cognitive performance, two 29 
reported mixed findings, and five reported no effect. When data was pooled, resveratrol 30 
supplementation had a significant effect on delayed recognition (SMD 0.39 [95% CI 0.08, 31 
0.70]; I2=0%; p=0.01; n=3 studies; n=166 participants) and negative mood (SMD -0.18 [95% 32 
CI -0.31, -0.05]; I2=0%; p=0.006; n=3 studies; n=163 participants). Included studies 33 
generally had low risk of bias and were moderate or high quality.  34 
Conclusion: The results of this review indicate that resveratrol supplementation might 35 
improve select measures of cognitive performance; however, the current literature is 36 
inconsistent and limited. 37 
Introduction 38 
Age-related cognitive decline, characterised by reduced functioning in mental processes such 39 
as attention regulation, memory capacity, and processing speed,1 can pose a substantial 40 
burden to the individual as it is associated with reduced functional independence and quality 41 
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of life.2,3 The societal impact of age-related cognitive decline is likely to be compounded by 42 
the global ageing population, with a predicted doubling in the number of persons aged 60 or 43 
older by 2050.4 While age-related cognitive decline is an inevitable part of ageing, there are 44 
large inter-individual differences in the rate of decline that are attributed to modifiable 45 
lifestyle factors such as exercise, body mass index, and dietary patterns.5 Moreover, a greater 46 
number of these risk factors pose a heightened risk of dementia and Alzheimer’s disease, 47 
which, in addition to their significant morbidity, are projected to cost the Australian economy 48 
one trillion dollars over the next forty years.6 Therefore, due to the global ageing population,4 49 
combined with the significant health and cost burden associated with cognitive diseases,7 it is 50 
imperative to investigate potential interventions that can ameliorate age-associated cognitive 51 
decline and reduce the impact of later-life brain disease. Dietary polyphenols have been 52 
investigated for their potentially beneficial effect on cognitive performance.8-11 Observational 53 
studies have reported polyphenol intake and adherence to polyphenol rich dietary patterns 54 
such as the Mediterranean diet to be associated with improved measures of cognitive 55 
performance.11,12 Several polyphenol-rich foods including various berries, green tea, and 56 
cacao have also demonstrated improved measures of cognitive performance in clinical 57 
trials.13    58 
Resveratrol is a polyphenol found in foods such as red grapes, berries, peanuts and red wine, 59 
and has been demonstrated in preclinical models to exhibit neuroprotective properties.14,15 60 
Resveratrol supplementation prevents streptozotocin-induced cognitive impairment and 61 
protects against hippocampal neurodegeneration and against learning impairment in rodent 62 
models.16,17 Additionally, resveratrol supplementation improved cognitive outcomes such as 63 
spatial memory and memory acquisition in primate18 and rodent19 models of ageing. While 64 
the exact mechanism of action is unknown, reseveratrol may act on multiple pathways 65 
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suggested to be involved in age-related cogntive decline including enhanced endothelial 66 
production of nitric oxide, oxidative stress reduction, inhibition of inflammation, and 67 
modulation of sirtuin gene expression.20,21 68 
If resveratrol supplementation provides a positive effect on human cognitive performance, 69 
resveratrol supplementation could be a viable, low-cost treatment intervention for preserving 70 
cognitive performance in the ageing population. Therefore, this systematic review and meta-71 
analysis aimed to examine the potential effect of resveratrol supplementation on cognitive 72 
performance and mood in adult humans.  73 
Methodology  74 
Literature search 75 
This review used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 76 
(PRISMA) guidelines as a methodological template.22 An initial systematic search of the 77 
following databases was conducted, without time limits, up to September 2016: Medline (via 78 
Scopus), CINAHL, Cochrane, Embase and Proquest. A further search was conducted in June 79 
2017 before submission to ensure all relevant studies were identified. A snowball search was 80 
conducted by searching for references published in relevant papers. Derived from the PICOS 81 
criteria (Table 1), the search terms used were (Adult OR human) AND (Resveratrol OR 82 
stillbenoid OR phytoalexin OR red wine OR red grape OR trans-resveratrol) AND (Cognitive 83 
performance OR cognition OR mental capacity).  84 
Study selection 85 
Eligible studies required the following criteria: used a randomized controlled trial study 86 
design; recruited both healthy and clinical adult human subjects (over 18); written in English, 87 
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and used an intervention of resveratrol supplementation (either standalone or in combination 88 
with other compounds). We did not include studies that investigated resveratrol-containing 89 
foods as food items contain a vast array of bioactive compounds which could influence 90 
results and in contrast to supplements, are relatively low in concentrations of resveratrol, and 91 
are unlikely to provide the therapeutic dose provided in previously reported supplementation 92 
studies.23,24 However, red wine and grapes have been the primary focus of resveratrol-related 93 
research and therefore, in order to reduce the number of search results while ensuring all 94 
relevant studies were captured, search terms relating to red wine and grapes were included 95 
while search terms relater to other food sources were excluded. Cross-sectional studies, 96 
reviews, abstracts, study protocols, conference papers, or those that did not report on any 97 
outcome of interest were excluded. Outcomes of interest for the study included any cognition 98 
measurements (e.g. memory, processing speed), mood, and cognitive fatigue. Articles were 99 
first screened for eligibility based on titles and abstracts by two investigators (JC and BA). If 100 
considered potentially eligible, the full text publication was retrieved and independently 101 
reviewed by two review authors (JC and BA). Disagreements were managed by discussion to 102 
reach consensus. 103 
Data Extraction  104 
Data extraction (conducted by JC and BA, and cross-checked by WM) included the following 105 
parameters: study design, sample size, total study period, population, timing of outcome 106 
measures, type of intervention, dose and duration of resveratrol supplementation, outcomes 107 
reported, results, study location and level of evidence. To perform the meta-analysis, we 108 
extracted the mean change score, or end-of-study values when change scores were not 109 
available, along with their associated variance (standard deviations [SD], standard error 110 
[SE]or 95% confidence intervals [CI]). For studies reporting more than one resveratrol 111 
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intervention arm, we extracted the arm of the highest dose or the resveratrol arm only in cases 112 
where the second resveratrol intervention had more than two active ingredients.  113 
Risk of Bias 114 
All studies were independently assessed for bias by three authors (JC and BA and WM) using 115 
the Cochrane Handbook for Systematic Reviews of Interventions checklist.25 This tool 116 
includes criteria for assessing sequence generation, allocation concealment, blinding of 117 
participants, blinding of personnel and outcome assessors, incomplete outcome data and 118 
selective outcome reporting, which assesses risk of bias as low, unclear or high. 119 
Disagreements were managed by consensus. All clinical studies were rated for evidence level 120 
using the National Health and Medical Research Council Hierarchy of Evidence.26 The 121 
certainty in the body of evidence for each outcome related to cognitive function for which we 122 
found data was assessed using the Grading of Recommendations, Assessment, Development 123 
and Evaluation (GRADE) tool,27 following steps and interpretation as specified in the 124 
GRADE Handbook.28 Determination of the GRADE level of evidence was determined 125 
independently by two authors (SM and WM), with disagreements managed by consensus. 126 
Data Synthesis and Analysis  127 
Due to the range of cognitive function tests used in the included studies, the Cattall–Horn–128 
Carroll cognitive framework was used to group differing cognitive function tests based on the 129 
frameworks proposed broad cognitive abilities and as used in previous nutraceutical trials.29 130 
When interventions and associated outcomes were assessed as sufficiently homogeneous, and 131 
when sufficient information was available from the studies, quantitative data were pooled 132 
into Review Manager (Version 5.3, The Cochrane Collaboration 2014) for meta-analysis. To 133 
calculate the overall treatment effect, the difference between the intervention and comparison 134 
7 
 
groups’ change scores from baseline to the end of follow-up was extracted. If change scores 135 
were not available, end of intervention values were extracted, assuming baseline values were 136 
similar.30 The appropriate variance from each individual study was used, either as the SD or 137 
calculated from the SEM or 95%CI. Meta-analysis of these values was performed using the 138 
DerSimonian and Laird random-effects model31 and checked using the fixed-effect model to 139 
ensure robustness and susceptibility to potential outliers. The I2 statistic was used to assess 140 
the inconsistencies between studies and describe the percentage of variability in effect. 141 
Heterogeneity was considered substantial if the I2 statistic was ≥50%. All effect sizes were 142 
calculated using the standardised mean differences (SMD) as all studies used a myriad of 143 
outcome measures/scales. Standardised mean difference effect sizes of <0.4 were considered 144 
small, 0.4 – 0.7 moderate, and >0.7 large.30 We considered a statistically significant finding 145 
with p-values <0.05. Meta-analyses with significant results were presented as a figure within 146 
the manuscript and meta-analyses with non-significant results were included as 147 
supplementary material. Publication bias was assessed by visual inspection of funnel plots.  148 
Results 149 
Three hundred and fifty articles were identified after the initial search with 115 of these 150 
omitted as duplicates. A further 201 did not meet the inclusion criteria. Of the remaining 34 151 
articles, 24 were excluded for reasons detailed in the PRISMA flow chart (Figure 1), leaving 152 
10 articles for inclusion in the final review. We conducted nine meta-analyses with eight 153 
studies being included in at least one meta-analysis (two studies excluded from meta-analyses 154 
due to insufficient available data or heterogenous study design).32,33  155 
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Study Characteristics 156 
The total sample size of the studies included in this systematic review was 372 subjects and 157 
individual study sample sizes ranged from 16 to 80 participants (Table 232-41). All studies 158 
were randomized double-blind controlled trials with five studies using cross-over designs. 159 
Nine studies used an inert placebo as the control group while Scholey et al.32 compared a red 160 
wine supplemented with resveratrol to a red wine intervention that was not supplemented 161 
with resveratrol. Three studies included healthy young adults (18-34 years old),35,37,38 two 162 
studies included healthy older adults (65-78),32,34 two included healthy overweight older 163 
adults,39,40 one included schizophrenic adults,41 one included older adults with mild cognitive 164 
decline,36 and one included adults with Type 2 Diabetes Mellitus (T2DM).33 The duration of 165 
the studies varied with six studies using chronic daily doses up to 26-weeks.34,36,37,39-41 The 166 
remaining four studies used single or multiple acute doses with 2-14 days washout between 167 
doses.  168 
Dosing regimen 169 
Studies used a dose of resveratrol ranging from 75 to 500mg and required subjects to 170 
consume in capsule form, with the exception of one study that used wine enriched with 171 
200mg resveratrol.32 No study reported any adverse side effects from supplementation. Four 172 
studies used a co-intervention of piperine or quercetin with the aim to increase bioavailability 173 
of resveratrol supplementation.36-39 174 
Outcome Measures 175 
Measures of cognition varied, with four studies using the Computerised Mental Performance 176 
Assessment System (COMPASS)32,35,37,38 to conduct the serial subtraction 3 and 7, Rapid 177 
Visual Image Processing (RVIP) test. Two studies also used the COMPASS to conduct serial 178 
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13 and 17’s and either a 3-back or N-back test;37,38 three studies used the Stroop Colour-179 
Word Test;33,40,41 three used variations of the Rey Auditory Verbal Learning Test 180 
(RAVLT);34,36,39 and two used the trail making task.33,34 Individual studies also included the 181 
following cognitive tests: the Computerized Multi-Tasking Test Battery;33 15-minute word 182 
recall;39 the Cambridge Semantic Memory Battery and the Double Span Task;34 and the 183 
Hopkins Verbal Learning Test and the Weschler Adult Intelligence Scale.41 184 
Study Results 185 
The reported between-group differences in cognition was mixed. Five studies reported 186 
significant improvements in some measures of cognitive performance. These included word 187 
retention (p=0.038),39 overall cognitive performance (p=0.020),34 semantic and verbal 188 
memory domains (p=0.041),34 and anxiety (p=0.025).34 Scholey et al.32 reported 189 
improvements in the Serial 7s test (p=0.009) in the intervention group (acute dose, 200 mg 190 
resveratrol enriched red wine) but that the control group (red wine only) reported 191 
improvements in the Serial 3s test (p=0.004). Wightman et al.37 also reported mixed results 192 
with the intervention group reporting both lower and higher performance measures compared 193 
to placebo in the COMPASS serial 7s, 17s and 3-back tests and measures of fatigue. Wong et 194 
al.33 reported improvements in performance index (accuracy/time) during a dual and multi-195 
tasking test battery in two of the three intervention doses (75mg and 300mg) compared to 196 
placebo but no improvement in accuracy alone. The remaining five studies reported no 197 
significant differences in cognitive measures. 198 
Processing speed  199 
A total of 8 studies involving a total of 267 participants measured visual processing speed 200 
outcomes,32-35,37,38,40,41 including RVIP reaction time,32,35,37,38 Stroop colour word test,33,40,41 201 
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and the Trail Making Test.33,34 Five studies with available data were entered into two separate 202 
meta-analyses which assessed differences in number of correct answers or the time taken to 203 
complete the task. Resveratrol supplementation did not significantly influence either measure 204 
of processing speed, in numbers correct (SMD -0.04 [95% CI -0.38, 0.31]; I2=0%; p=0.84; 205 
n=3 studies; n=86 participants), or time taken, although there was a near significant trend 206 
towards decreased time taken(SMD -0.23 [95% CI -0.48, 0.01]; I2=0%; p=0.06; n=5 studies; 207 
n=211 participants). 208 
Number facility  209 
Number facility was reported in 4 studies including 123 participants.32,35,37,38 Reported 210 
number facility outcomes included serial 3’s,32,35 serial 7’s,32,35,37,38 serial 13’s,37,38 and serial 211 
17’s.37,38 Meta-analysis of three studies35,37,38 with available data was conducted, which 212 
included serial number facility outcomes reported as serials correct and serials incorrect. 213 
Meta-analysis showed no significant effect of resveratrol supplementation on serials correct 214 
(SMD -0.17 [95% CI -0.38, 0.05]; I2=0%; p=0.12; n=3 studies; n=86 participants) or serials 215 
incorrect (SMD 0.04 [95% CI -0.21, 0.28]; I2=25%; p=0.78; n=3 studies; n=86 participants). 216 
Memory  217 
Memory was measured by RAVLT34,36,39, N-back accuracy,37,38 and the Hopkins Verbal 218 
Learning Test41 by a total of six studies encompassing 244 participants. There was sufficient 219 
information provided by three studies to perform meta-analyses on the RAVLT subset scores; 220 
delayed recall, delayed recognition, and learning ability. Resveratrol supplementation had a 221 
significant effect but low effect size on delayed recognition (SMD 0.39 [95% CI 0.08, 0.70]; 222 
I2=0%; p=0.01; n=3 studies; n=166 participants; Figure 2)34,36,39; however, no significant 223 
effect on delayed recall (SMD 0.23 [95% CI -0.16, 0.63]; I2=38%; p=0.25; n=3 studies; 224 
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n=166 participants) or learning ability (SMD 0.28 [95% CI -0.26, 0.81]; I2=65%; p=0.31; n=3 225 
studies; n=166 participants).  226 
Mood 227 
A total of five studies involving a total of 203 participants reported a variety of mood-related 228 
outcomes following resveratrol supplementation.32,34,35,37,38 Mood was measured using the 229 
following questionnaires: Profile of Mood States (POMS) questionnaire,34,37 the Bond-Lader 230 
Visual Analogue Mood scales,32 the Centre for Epidemiologic Studies Depression scale,34 231 
and visual analogue scales.35,38 The results of two meta-analysis report a non-significant 232 
change in ratings of positive mood (SMD -0.02 [95% CI -0.28, 0.24]; I2=0%; p=0.88; n=3 233 
studies; n=163 participants) and a significant improvement in negative mood (SMD -0.18 234 
[95% CI -0.31, -0.05]; I2=0%; p=0.006; n=3 studies; n=163 participants; Figure 3)34,37,38 with 235 
a low effect size.  236 
Risk of Bias assessment and certainty of evidence-base 237 
Figure 4 shows the risk of bias across the included studies. Overall, the assessment of bias 238 
reported generally low risk of bias across all domains, particularly for reporting bias and 239 
performance bias for all studies. Five studies were rated as high risk of other bias due to the 240 
inclusion of additional bioactive compounds to the intervention which may have influenced 241 
the results.32,34,36-38 Visual inspection of funnel plots provided no evidence of publication 242 
bias. Using the GRADE tool, all outcomes were rated at high or moderate quality except for 243 
learning ability which was rated as low quality due to imprecision and significant 244 
heterogeneity (I2 of 65%) (Table 3). Imprecision due to small sample sizes of individual 245 
meta-analyses was the most common reason for downgrading the quality rating.  246 
12 
 
Discussion  247 
The aim of this review was to systematically evaluate the strength of current research 248 
regarding the efficacy of resveratrol supplementation in cognitive performance. Although 249 
there is promising preclinical research to suggest resveratrol supplementation influences 250 
cognition,16,17,20 the published clinical research currently provides mixed results, with 5 of 10 251 
studies reporting no significant effect on cognitive performance. Furthermore, the results of 252 
our meta-analysis and GRADE assessment reported moderate to high confidence that 253 
resveratrol supplementation has no significant effect on most outcomes in the general 254 
population, excepting a small effect in improving delayed recognition and negative mood.  255 
Delayed recognition appears to decline in older adults and mood disorders are prevalent 256 
within all age groups.42,43 Resveratrol is a relatively low-cost, widely-available, and well-257 
tolerated intervention which may be an effective intervention for these outcomes. However, 258 
given the small effect size and limited sample sizes of included studies, the results of our 259 
meta-analysis should be interpreted with caution and clinical judgment should be used when 260 
using resveratrol supplementation in a clinical setting.  261 
The length of the trial periods varied greatly from one day to six months with trials using a 262 
shorter duration generally finding no significant results compared to longer term trials. Due to 263 
the small number of studies, a sensitivity analysis was unable to be conducted for each meta-264 
analysis to assess this. However, of the studies that reported significant effects from 265 
resveratrol supplementation, two of three longest running trials reported significant 266 
improvements in some measures of cognitive performance.34,39 Therefore, these results 267 
suggest that long-term resveratrol supplementation may be required to achieve improvements 268 
in cognitive measures. However, these results contrast with Kobe et al.36 which also 269 
conducted a 26-week study but reported no significant differences in cognitive performance. 270 
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Furthermore, there was clinical heterogeneity in the cohorts investigated with some including 271 
young healthy adults while others included older adults and those with diabetes, mild 272 
cognitive impairment or schizophrenia. Two studies suggest that resveratrol supplementation 273 
may have more pronounced effects in certain populations with worse cognitive performance, 274 
that being older individuals or populations with chronic diseases.32,33 It may be that 275 
populations with cognitive impairment will have more distinguished performance differences 276 
than high performing populations. However, included studies that recruited older participants 277 
or participants with chronic diseases did not report consistently positive improvements in 278 
cognition. 279 
The dose of resveratrol used in the included studies ranged from 75 to 500mg with no clear 280 
trend related to the efficacy of the intervention, suggesting that the differences in results 281 
between studies may not be due to the dosage used. The poor bioavailability of resveratrol, 282 
however,  may account for the variation of results.25 Some studies included additional 283 
nutrients such as piperine and quercetin to improve the bioavailability of resveratrol. In 284 
animal studies, piperine significantly enhances maximum serum resveratrol levels and area 285 
under the curve when compared to resveratrol alone44 and thus, was used by Whitman et 286 
al.37,38 in two separate studies. However, results from their acute trial38 reported no significant 287 
improvements in cognition and their chronic-dosing trial37 reported inconsistent changes in 288 
some measures of cognitive testing. Two of the included studies supplemented 320-350 mg 289 
of quercetin in addition to resveratrol,36,39 which is believed to inhibit the sulphation of 290 
resveratrol in the body and increase its bioavailability.45 While the addition of these nutrients 291 
may improve bioavailability of resveratrol, it may also confound the results as it is unclear if 292 
a treatment effect (or lack of effect) is due to resveratrol or from the additional bioactive 293 
nutrients, which may have interacted with the effect of resveratrol or acted independently. 294 
Furthermore, Whiteman et al.37 demonstrated that plasma resveratrol metabolites can 295 
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accumulate with chronic dosing which suggests chronic administration of resveratrol may be 296 
an alternative strategy to improving plasma concentrations.  297 
There are multiple food sources that are rich in a variety of polyphenols. These include, but 298 
are not limited to, green tea,8 cacao,10 and berries,9; which have all been demonstrated to 299 
affect cognitive performance. The total polyphenol intake of participant habitual diet and 300 
consumption of polyphenol-rich foods prior to measurement was, to varying degrees, 301 
controlled for in many of the included studies. Strategies included asking participants to 302 
maintain their usual diet,34,39,41 abstain from resveratrol or polyphenol rich foods,40,41 303 
monitoring dietary records for gross changes in diet,34,37,40 and providing detailed lists of 304 
polyphenol rich foods to limit.40 However, while many of these strategies could reduce 305 
polyphenol variation during the intervention period, they are less likely to control for group 306 
differences in polyphenol intake. Therefore, measures to control for group differences in total 307 
polyphenol intake such as dietetic education and food monitoring may be beneficial for future 308 
clinical studies.  309 
Finally, due to the small sample sizes and few reported details on power calculations in many 310 
of the included studies, it is possible that many require additional statistical power to detect a 311 
significant difference in cognitive scores. For example, Wong et al.40 stated being sufficiently 312 
powered to detect changes in flow mediated dilation, but attributed the lack of effect size in 313 
cognitive outcomes to a lack of statistical power. However, our meta-analyses of pooled 314 
results determined resveratrol supplementation to improve only in one of the seven outcomes 315 
we analysed.  316 
A limitation of our meta-analysis was that despite the wide-range of similar cognitive tests 317 
used in the included studies, there was a lack of homogeneity in how the tests were reported 318 
which limited the number of studies that could be included for analysis. Future trials are 319 
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encouraged to provide standardized results or supplementary material and/or datasets to assist 320 
with future meta-analyses in this area. 321 
Conclusion 322 
The current literature does not provide consistent support for the use of resveratrol 323 
supplementation on improving cognitive performance. In some instances, resveratrol has 324 
been shown to enhance some cognitive performance measures; however, there is limited 325 
consistency between studies. Future trials that are sufficiently powered, utilise longer 326 
intervention periods, and address confounding issues including background polyphenol intake 327 
and bioavailability are required  328 
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Figure 1. PRISMA Flow Diagram 499 
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Figure 2. Meta-analysis on the effect of resveratrol supplementation on delayed recognition 506 
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Figure 3. Meta-analysis on the effect of resveratrol supplementation on negative mood 542 
543 
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Figure 4. Risk of bias: review authors' judgments’ on each risk of bias item presented as 544 
percentages across all included studies (n=10).  545 
 546 
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Table 1. PICOS criteria for research question 547 
Population Adult humans (healthy or chronic disease 
populations) 
Intervention Resveratrol supplementation  
Comparator Placebo or control intervention 
Outcome Cognitive function domains or mood 
Setting Any 
 548 
 549 
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Table 2. Summary table of included studies 550 
Author/ 
Date 
Study 
design 
Country 
Level of 
Evidenc
e 
Sampl
e size 
(n) 
Total 
Study 
period 
Population 
details 
Outcomes 
measured at: 
Interventio
n 
Cognitive 
outcomes 
Mood 
outcomes 
Results 
Acute consumption studies  
Kennedy 
et al. 
201035 
Randomized
, double 
blind 
placebo 
controlled, 
cross-over 
trial 
United 
Kingdo
m 
II 24 
3 x 1 day, 
7 day 
wash out 
Healthy 
adults 
Age (years, 
mean 
(range)): 
20.17 (18-25) 
BMI: Not 
reported 
Baseline, 45 
minutes 
post-
consumption 
250mg 
trans-
resveratrol 
OR 500mg 
trans-
resveratrol 
OR placebo 
COMPASS 
cognitive 
assessment 
system tests 
(Serial 
subtractions 
3 and 7, 
RVIP).  
Mental 
fatigue using 
a visual 
analogue 
scale 
No significant, 
treatment-
related 
differences on 
cognitive task 
performance 
and mental 
fatigue 
Scholey 
et al. 
201432 
Randomized
, double 
blind, cross-
over trial 
Australia II 16 
2 x 1 day, 
minimum 
48-hour 
washout 
Healthy older 
adults 
Age (years, 
mean±std): 
70.44±4.37  
BMI: Not 
reported 
Baseline and 
60 minutes 
post-
consumption 
100ml red 
wine OR 
100ml red 
wine 
enriched 
with 200 
mg 
resveratrol  
COMPASS 
cognitive 
assessment 
system tests 
(serial 
subtractions 
3 and 7, 
RVIP),  
Mood using 
the Bond-
Lader Visual 
Analogue 
Mood scales 
Red wine 
group made 
more 
responses with 
Serial 3s 
(p=0.004), 
Resveratrol 
group made 
more 
responses with 
Serial 7s 
(p=0.009). No 
other 
significant 
effects 
Wightma
n et al. 
201438 
Randomized
, double 
blind, 
placebo 
controlled, 
cross-over 
trial 
United 
Kingdo
m 
II 23 
3 x 1 day 
visits to 
clinic 
(conducte
d 2-14 
days 
apart) 
Healthy 
adults 
Age (years, 
mean±std): 
21±3.2 
BMI 
(mean±std):  
24.2±2.38 
kg/m2 
Baseline and 
40 minutes 
post-
consumption 
250mg 
trans-
resveratrol 
OR 250mg 
trans-
resveratrol 
and 20mg 
of piperine 
OR placebo 
COMPASS 
cognitive 
assessment 
system tests 
(Serial 
subtractions 
7, 13 and 17, 
RVIP and N-
back),  
Mood using a 
visual 
analogue 
scale 
No significant 
treatment-
related 
differences in 
cognitive or 
mood 
measures 
27 
 
Wong et 
al. 201633 
Randomized
, double-
blind 
placebo 
controlled, 
cross-over 
trial  
Australia II 36 
4 x 1 day, 
7 day 
wash out 
T2DM adults 
Age (years, 
mean±std): 
46.40±11.18 
(Resveratrol 
group), 
41.00±7.87 
(Control 
group) 
BMI (mean): 
30.3 kg/m2 
75 min post 
consumption
. 
75, 150, 
300mg 
trans-
resveratrol 
OR placebo 
Computerize
d Multi-
Tasking Test 
Battery 
comprising, 
Stroop 
Color-Word 
test, N-back 
task, Visual 
Warning and 
High 
Number Tap, 
Trial Making 
Task and 
Serial 
Subtraction 3 
  
Performance 
index 
(accuracy/time
) was 
improved in 
75mg and 
300mg doses 
compared to 
placebo 
(P<0.001 for 
both doses). 
No other 
significant 
between group 
differences 
reported 
Chronic consumption studies 
Wong et 
al. 201340 
Randomized
, double 
blind, 
placebo 
controlled, 
cross-over 
trial 
Australia II 28 
2 x 6 
weeks 
Healthy 
obese adults  
Age (years, 
mean±std): 
61±1.3 
BMI 
(mean±std): 
33.3±0.6 
kg/m2 
Baseline, 
week 6 and 
week 12 
75mg 
trans-
resveratrol 
OR placebo 
Stroop 
Color-Word 
Test 
  
No significant 
improvement 
in cognition. 
Witte et 
al. 201439 
Pair-wise 
matched, 
double 
blind, 
placebo 
controlled, 
parallel-
groups trial. 
German
y  
II 46 26 weeks 
Healthy 
overweight 
older adults  
Age (years, 
mean±std): 
64.8±6.8 
(Resveratrol 
group), 
63.7±5.3 
(Control 
group) 
Baseline and 
26 weeks 
200mg 
resveratrol 
and 320mg 
of 
quercetin 
OR placebo 
RAVLT 
(German 
version) and 
15-minute 
word recall 
  
Significant 
improvement 
in word 
retention 
(memory 
function) from 
baseline to 26 
weeks in 
resveratrol 
group, 
compared to 
28 
 
BMI (range): 
25–30 kg/m2 
placebo 
(p=0.038) 
Wightma
n et al. 
201537 
Randomized
, double 
blind, 
placebo 
controlled, 
parallel-
groups trial. 
United 
Kingdo
m 
II 60 28 days  
Healthy 
adults 
Age (years, 
mean 
(range)): 
20.52 (18-29) 
BMI: Not 
reported 
Day 1, 
Baseline and 
45 minutes 
post-
consumption
. Day 28, 
prior to 
consumption 
and 45 min 
post- 
consumption 
500mg 
trans-
resveratrol 
and 10 mg 
piperine 
OR placebo 
COMPASS 
cognitive 
assessment 
system tests 
(Serial 
subtractions 
7, 13 and 17, 
RVIP and 3-
back) 
Mental illness 
using the 
General 
Health 
Questionnaire
, Mood using 
the Profile of 
Mood States, 
At Day 28 
timepoint, 
prior to 
consumption, 
resveratrol 
group reported 
improved 
accuracy in 3-
back test 
(p=0.006). In 
an ANOVA 
analysis 
(treatment × 
repetition × 
day), the 
resveratrol 
group had 
fewer incorrect 
responses in 
the serial 7's 
test (P=0.016), 
fewer correct 
responses in 
the serial 17's 
test (P=0.019), 
and fewer 
29 
 
incorrect 
responses in 
the 3-back test 
(P=0.021). 
Resveratrol 
significantly 
improved 
fatigue (P = 
0·003) 
Zortea et 
al. 201641 
Randomized
, double 
blind, 
placebo 
controlled, 
parallel-
groups trial. 
Brazil II 19 30 days 
Schizophreni
c men  
Age (years, 
mean±std): 
46.40±11.18 
(Resveratrol 
group), 
41.00±7.87 
(Control 
group) 
BMI: Not 
reported 
Baseline and 
30 days 
200mg 
trans-
resveratrol 
OR placebo 
Hopkins 
Verbal 
Learning 
Test, Stroop 
Color and 
Word Test, 
and Weschler 
Adult 
Intelligence 
Scale 
  
No significant 
between-group 
differences 
reported.  
Evans et 
al. 201734 
Randomized
, double 
blind, 
placebo 
controlled, 
parallel-
groups trial. 
Australia II 80 14 weeks 
Post-
menopausal 
women  
Age (years, 
mean±std):  
61.5±1.1 
(Resveratrol 
group), 
61.5±1.2 
(Control 
group) 
BMI: 
26.8±0.8 
(Resveratrol 
group), 
26.6±0.8 
(Control 
group) 
Baseline and 
14 weeks 
150mg 
trans-
resveratrol 
OR placebo 
RAVLT, the 
Cambridge 
Semantic 
Memory 
Battery, the 
Double Span 
Task, and the 
Trail Making 
Task 
Mood using 
the Profile of 
Mood States 
questionnaire, 
Depression 
using the   
Centre for 
Epidemiologi
c Studies 
Depression 
scale  
Compared to 
placebo, the 
intervention 
significantly 
improved 
overall 
cognitive 
performance 
(p=0.003), 
semantic 
memory 
(p=0.043) and 
verbal memory 
(p=0.043). 
Adjusting for 
depressive 
symptoms, 
verbal memory 
30 
 
(p=0.037) and 
overall 
cognitive 
performance 
(p=0.023) 
remained 
significantly 
improved by 
resveratrol.  
Anxiety (as 
measured by 
POMS) was 
significantly 
reduced (p = 
0.025) in the 
intervention 
group 
compared to 
placebo. No 
significant 
changes were 
observed in 
other 
components of 
cognitive 
performance 
or mood 
31 
 
Kobe et 
al. 201736 
Randomized
, double 
blind, 
placebo 
controlled, 
parallel-
groups trial. 
German
y 
II 40 26 weeks 
Mild 
cognitive 
impairment  
Age (years, 
mean±std):  
65±9 
(Resveratrol 
group), 69±7 
(Control 
group) 
BMI: 26±3 
(Resveratrol 
group), 26±3 
(Control 
group) 
Baseline and 
26 weeks 
200mg 
resveratrol 
and 350mg 
quercetin 
OR placebo  
RAVLT 
(German 
version) 
  
No significant 
difference in 
cognitive 
outcomes 
Abbreviations: CBF, cerebral blood flow; COMPASS, Computerized Mental Performance Assessment System; FMD, flow mediated dilation; POMS, Profile of Mood 
States; RAVLT, Rey Auditory Verbal Learning Test; RVIP, Rapid Visual Information Processing; 
 551 
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Table 3: GRADE assessment of resveratrol supplementation compared to control for enhancing cognitive performance  552 
 Quality assessment 
№ of 
patients 
Effect 
Quality 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
consideration
s 
R
es
v
er
a
tr
o
l 
su
p
p
le
m
en
ta
ti
o
n
  
P
la
ce
b
o
 
Absolute 
(95% CI) 
Processing speed: number of correct answers  
3 Randomise
d trials  
Not 
serious  
Not serious  Not serious  Seriousa  None  67 64 SMD 0.04 SD lower 
(0.38 lower to 0.31 higher)  
⨁⨁⨁◯ 
MODERATE 
Processing speed: time taken to complete the task 
4 Randomise
d trials  
Not 
serious  
Not serious  Not serious  Seriousa  None  110 110 SMD 0.23 SD lower 
(0.48 lower to 0.01 higher)  
⨁⨁⨁◯ 
MODERATE 
Number facility: serials correct  
33 
 
 Quality assessment 
№ of 
patients 
Effect 
Quality 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
consideration
s 
R
es
v
er
a
tr
o
l 
su
p
p
le
m
en
ta
ti
o
n
  
P
la
ce
b
o
 
Absolute 
(95% CI) 
8 outcomes 
included 
from 3 
studies  
Randomise
d trials  
Not 
serious  
Not serious  Not serious  Not serious  None  179 170 SMD 0.17 SD lower 
(0.38 lower to 0.05 higher)  
⨁⨁⨁⨁ 
HIGH  
Number facility: serials incorrect 
8 outcomes 
included 
from 3 
studies 
Randomise
d trials  
Not 
serious  
Not serious  Not serious  Not serious  None  179 170 SMD 0.04 SD higher 
(0.21 lower to 0.28 higher)  
⨁⨁⨁⨁ 
HIGH  
Memory: delayed recognition  
34 
 
 Quality assessment 
№ of 
patients 
Effect 
Quality 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
consideration
s 
R
es
v
er
a
tr
o
l 
su
p
p
le
m
en
ta
ti
o
n
  
P
la
ce
b
o
 
Absolute 
(95% CI) 
3 outcomes 
included 
from 3 
studies 
Randomise
d trials  
Not 
serious  
Not serious  Not serious  Seriousa  None  79 87 SMD 0.39 SD higher 
(0.08 higher to 0.7 higher)  
⨁⨁⨁◯ 
MODERATE 
Memory: delayed recall  
3 outcomes 
included 
from 3 
studies 
Randomise
d trials  
Not 
serious  
Not serious  Not serious  Seriousa  None  79 87 SMD 0.23 SD higher 
(0.16 lower to 0.63 higher)  
⨁⨁⨁◯ 
MODERATE 
Memory: learning ability  
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 Quality assessment 
№ of 
patients 
Effect 
Quality 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
consideration
s 
R
es
v
er
a
tr
o
l 
su
p
p
le
m
en
ta
ti
o
n
  
P
la
ce
b
o
 
Absolute 
(95% CI) 
3 outcomes 
included 
from 3 
studies 
Randomise
d trials  
Not 
serious  
Seriousb Not serious  Seriousa None  79 87 SMD 0.28 SD higher 
(0.26 lower to 0.81 higher)  
⨁⨁◯◯ 
Low  
Mood: positive mood 
4 outcomes 
included 
from 3 
studies 
Randomise
d trials 
Not 
serious 
Not serious Not serious Seriousa None 110 115 SMD 0.17 SD lower 
(0.43 lower to 0.09 higher) 
⨁⨁⨁◯ 
MODERATE 
Mood: negative mood 
36 
 
 Quality assessment 
№ of 
patients 
Effect 
Quality 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
consideration
s 
R
es
v
er
a
tr
o
l 
su
p
p
le
m
en
ta
ti
o
n
  
P
la
ce
b
o
 
Absolute 
(95% CI) 
15 
outcomes 
included 
from 3 
studies 
Randomise
d trials 
Not 
serious 
Not serious Seriousc Not serious None 450 478 SMD 0.18 SD lower 
(0.31 lower to 0.05 lower) 
⨁⨁⨁◯ 
MODERATE 
CI: Confidence interval; SMD: Standardised mean difference 553 
Explanations 554 
a. Although the confidence intervals were narrow, the total sample size of all included studies was very low leading to lack of confidence in the precision estimate. 555 
b. Heterogeneity was significant with an I-squared of 65%  556 
c. The pooled analysis for negative mood used negative mood items from multiple mood questionnaires rather than the total score from one validated tool; therefore, we have 557 
some uncertainty about how the results directly reflect negative mood. 558 
